Vanda Pharmaceuticals reported a total revenue of $47.5 million, a decrease of 24% compared to Q1 2023. Net loss was $4.1 million, compared to net income of $3.3 million in Q1 2023. Cash, cash equivalents and marketable securities was $394.1 million as of March 31, 2024, representing an increase to Cash of $5.9 million compared to December 31, 2023.
Total net product sales were $47.5 million, a 24% decrease compared to the first quarter of 2023.
Fanapt® net product sales were $20.6 million, a 10% decrease compared to the first quarter of 2023.
HETLIOZ® net product sales were $20.1 million, a 49% decrease compared to the first quarter of 2023 due to generic competition.
Cash, cash equivalents and marketable securities increased by $5.9 million to $394.1 million.
Given continuing uncertainties surrounding the U.S. market for HETLIOZ® for the treatment of Non-24 as a result of continued generic competition in the U.S. and the upcoming commercial launches for Fanapt® in acute bipolar I disorder and PONVORY® in multiple sclerosis, Vanda is unable to provide 2024 financial guidance at this time.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance